BRPI0614080A2 - Composição e método para a preparação de uma cefalosporina nanoparticulada, para o tratamento de doença bacteriana e para a prevenção e/ou tratamento de osteoporose - Google Patents

Composição e método para a preparação de uma cefalosporina nanoparticulada, para o tratamento de doença bacteriana e para a prevenção e/ou tratamento de osteoporose

Info

Publication number
BRPI0614080A2
BRPI0614080A2 BRPI0614080A BRPI0614080A BRPI0614080A2 BR PI0614080 A2 BRPI0614080 A2 BR PI0614080A2 BR PI0614080 A BRPI0614080 A BR PI0614080A BR PI0614080 A BRPI0614080 A BR PI0614080A BR PI0614080 A2 BRPI0614080 A2 BR PI0614080A2
Authority
BR
Brazil
Prior art keywords
treatment
nanoparticulate
cephalosporin
composition
osteoporosis
Prior art date
Application number
BRPI0614080A
Other languages
English (en)
Inventor
Jenkins Scott
Liversidge Gary
Stark Paul
G Devane John
Fanning Niall
Singh Rekhi Gurvinder
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of BRPI0614080A2 publication Critical patent/BRPI0614080A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIÇÃO E MÉTODOS PARA A PREPARAÇÃO DE UMA CEFALOSPORINA NANOPARTICULADA, PARA O TRATAMENTO DE DOENÇA BACTERIANA E PARA A PREVENÇÃO E/OU TRATAMENTO DE OSTEOPOROSE. A presente invenção é dirigida a composições que incluem um antibiótico nanoparticulado tendo biodisponibilidade aperfeiçoada. Preferivelmente, o antibiótico compreende partículas de cefalosporina nanoparticuladas com um tamanho de partícula médio eficaz de menos que cerca de 2000 nm e é útil no tratamento de infecção bacteriana. A invenção também se relaciona a uma composição de liberação controlada compreendendo uma cefalosporina ou uma cefalosporina nanoparticulada que, em operação, fornece a droga de uma maneira pulsada ou bimodal para o tratamento de infecção bacteriana. As partículas de cefalosporina nanoparticuladas podem ser formuladas como um sistema de administração de droga de liberação controlada por meio do qual as partículas são revestidas uma ou mais vezes com um ou mais materiais de revestimento de polímero hidrofílico ou hidrofóbico natural ou sintético ou dispersas através de toda uma matriz de polímero hidrofílico e/ou hidrofóbico natural ou sintético.
BRPI0614080A 2005-05-16 2006-05-16 Composição e método para a preparação de uma cefalosporina nanoparticulada, para o tratamento de doença bacteriana e para a prevenção e/ou tratamento de osteoporose BRPI0614080A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68126505P 2005-05-16 2005-05-16
PCT/US2006/018835 WO2008010784A1 (en) 2005-05-16 2006-05-16 Nanoparticulate and controlled release compositions comprising a cephalosporin

Publications (1)

Publication Number Publication Date
BRPI0614080A2 true BRPI0614080A2 (pt) 2017-07-25

Family

ID=38957038

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0614080A BRPI0614080A2 (pt) 2005-05-16 2006-05-16 Composição e método para a preparação de uma cefalosporina nanoparticulada, para o tratamento de doença bacteriana e para a prevenção e/ou tratamento de osteoporose

Country Status (14)

Country Link
US (1) US20090269400A1 (pt)
EP (1) EP1915139A1 (pt)
JP (1) JP2008540691A (pt)
KR (1) KR20080026109A (pt)
CN (1) CN101287453A (pt)
AU (1) AU2006344711A1 (pt)
BR (1) BRPI0614080A2 (pt)
CA (1) CA2609296A1 (pt)
EA (1) EA200702518A1 (pt)
IL (1) IL187431A0 (pt)
MX (1) MX2007014363A (pt)
NO (1) NO20076456L (pt)
WO (1) WO2008010784A1 (pt)
ZA (1) ZA200709761B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2498903A4 (en) * 2009-11-09 2013-10-30 Univ Texas METHOD USING EMULSION MATRIX FOR FORMING SMALL PARTICLES OF HYDROPHOBIC AGENTS WITH SURFACE ENRICHED HYDROPHILIC CHARACTER BY ULTRA FAST FREEZING
CN101874784B (zh) * 2010-03-18 2011-12-14 贝沃特医药技术(上海)有限公司 析出结晶药物缓控释微球粒及其制备方法
WO2011146583A2 (en) 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
WO2014033077A1 (en) 2012-08-28 2014-03-06 Dsm Sinochem Pharmaceuticals Netherlands B.V. Composition comprising an antibiotic and a beta-lactamase inhibitor, wherein at| least one of them is in the form of mini-tablets
CN103980480B (zh) * 2013-02-07 2018-08-17 杨子剑 一种接枝药物的聚合物的制备和用途
KR101509168B1 (ko) * 2013-06-10 2015-04-06 한국화학연구원 세팔로스포린 항생제의 서방형 제제 및 이를 포함하는 서방형 약제학적 조성물
CN103330697B (zh) * 2013-06-27 2015-03-11 深圳致君制药有限公司 一种头孢丙烯胶囊及其制备方法
RO132297A2 (ro) * 2014-12-01 2017-12-29 Sun Pharmaceutical Industries Limited Compoziţie cu cefpodoxim proxetil cu eliberare extinsă
CN112675152A (zh) * 2020-12-25 2021-04-20 厦门金达威生物科技有限公司 一种nmn缓释肠溶性微胶囊及其制备方法
CN115487154B (zh) * 2022-11-17 2023-02-21 山东国邦药业有限公司 一种盐酸多西环素颗粒剂的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5264610A (en) * 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
US5935496A (en) * 1993-04-29 1999-08-10 Morton International, Inc. Salt pelletizing method
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5872104A (en) * 1994-12-27 1999-02-16 Oridigm Corporation Combinations and methods for reducing antimicrobial resistance
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
AT413383B (de) * 1998-01-09 2006-02-15 Sandoz Ag Verfahren zur isolierung eines diastereoisomerengemisches von cefpodoxim proxetil
JP4613275B2 (ja) * 1998-11-02 2011-01-12 エラン ファーマ インターナショナル,リミティド 多粒子改質放出組成物
IN191496B (pt) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
KR100342944B1 (ko) * 1999-11-08 2002-07-02 민경윤 고순도 세프포독심 프록세틸의 제조방법
AU2001255515A1 (en) * 2000-09-20 2002-04-02 Skyepharma Canada Inc. Stabilised fibrate microparticles
MXPA03007678A (es) * 2001-02-27 2004-03-16 Ranbaxy Lab Ltd Composicion farmaceutica oral de proxetil cefpodoxima.
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
ATE419835T1 (de) * 2002-05-06 2009-01-15 Elan Pharma Int Ltd Nystatin-nanopartikelzusammensetzungen
IL160095A0 (en) * 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs

Also Published As

Publication number Publication date
JP2008540691A (ja) 2008-11-20
AU2006344711A1 (en) 2008-01-24
CA2609296A1 (en) 2006-11-16
IL187431A0 (en) 2011-08-01
NO20076456L (no) 2008-02-13
KR20080026109A (ko) 2008-03-24
EP1915139A1 (en) 2008-04-30
US20090269400A1 (en) 2009-10-29
MX2007014363A (es) 2009-04-15
CN101287453A (zh) 2008-10-15
EA200702518A1 (ru) 2008-04-28
WO2008010784A1 (en) 2008-01-24
ZA200709761B (en) 2008-12-31

Similar Documents

Publication Publication Date Title
BRPI0614080A2 (pt) Composição e método para a preparação de uma cefalosporina nanoparticulada, para o tratamento de doença bacteriana e para a prevenção e/ou tratamento de osteoporose
Prasanna et al. Sustained release of amoxicillin from hydroxyapatite nanocomposite for bone infections
Pajares-Chamorro et al. Silver-doped bioactive glass particles for in vivo bone tissue regeneration and enhanced methicillin-resistant Staphylococcus aureus (MRSA) inhibition
Uskoković et al. In vitro analysis of nanoparticulate hydroxyapatite/chitosan composites as potential drug delivery platforms for the sustained release of antibiotics in the treatment of osteomyelitis
Sivakumar et al. Incorporation of antimicrobial macromolecules in acrylic denture base resins: a research composition and update
Ernst et al. Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions
Barreras et al. Chitosan nanoparticles enhance the antibacterial activity of chlorhexidine in collagen membranes used for periapical guided tissue regeneration
Saifullah et al. Controlled-release approaches towards the chemotherapy of tuberculosis
Petersen Triclosan antimicrobial polymers
WO2007086914A3 (en) Nanoparticulate clopidogrel formulations
NO20080202L (no) Nanopartikulaere clopidogrel og aspirin kombinasjonsformuleringer
Palanikumar et al. Influence of particle size of nano zinc oxide on the controlled delivery of Amoxicillin
BRPI0416239A (pt) método para preparar partìculas de submìcron de paclitaxel
BRPI0807569A8 (pt) Péletes compreendendo uma matriz de substância ativa resistentes ao suco gástrico
Sun et al. Preparation and application of collagen scaffold-encapsulated silver nanoparticles and bone morphogenetic protein 2 for enhancing the repair of infected bone
MXPA05014158A (es) Estructuras absorbentes que comprenden particulas polimericas superabsorbentes recubiertas.
PE20080899A1 (es) Composiciones en nanoparticulas
Tiwari et al. Review on surface treatment for implant infection via gentamicin and antibiotic releasing coatings
Yun et al. Application of antibacterial nanoparticles in orthodontic materials
Chai et al. Poly‐cyclodextrin functionalized porous bioceramics for local chemotherapy and anticancer bone reconstruction
Spoiala et al. The SiO2/ZnO composite materials for cosmetic creams
Abdulkareem Role of Potential Nanomateriales in Reducing Bacterial Resistance against Antibiotics (A Review).
EA200800092A1 (ru) Композиции в виде наночастиц и с контролируемым высвобождением, включающие арил-гетероциклические соединения
Lewis Antibiotic-free antimicrobial poly (methyl methacrylate) bone cements: A state-of-the-art review
Yu et al. Comprehensive biosafety assessment of Ag-ZnO/talc nanomaterials: Implications for antibacterial applications

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law

Free format text: REFERENTE A PETICAO NO 20070163006/RJ DE 19/11/2007.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: O DESPACHO 6.7 DA RPI 2140 DE 10/01/2012 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B11M Decision cancelled [chapter 11.13 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]